Merck submitted a nonbinding offer for the smaller biotech earlier in the year, according to a media report citing people ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...

Artisan Partners, an investment management company, released its “Artisan Value Fund” first quarter 2025 investor letter. A ...

The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

The National Legal and Policy Center, a right-wing advocacy and watchdog group, had asked the company to revisit its DEI ...

After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

Amid ongoing uncertainty around funding for the NIH and what it could mean for U.S. innovation, a top Merck executive ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An ...